Folate forms compared: 5-MTHF vs folinic acid vs folic acid

“Folate” on a supplement label can mean at least three very different molecules. They share an umbrella name and a similar spot on the nutrition facts panel. They do not share the same biology. For patients with MTHFR variants — roughly 30–40% of the population — the form on the label can be the difference between a supplement that works and one that mostly circulates in the blood, unused.

Here’s the clean comparison: what each form is, what the body does with it, and how to decide.

The three forms, in plain terms

Folic acid is the fully synthetic form, invented in the 1940s. It doesn’t exist in nature. It’s cheap, stable, shelf-ready, and what the US uses to fortify bread, pasta, cereal, and most mass-market multivitamins.

Folinic acid (5-formyltetrahydrofolate) is a partially reduced, partially activated folate. It’s natural — your body produces it and you can eat it in leafy greens. Pharmaceutically it’s sold as leucovorin and used to rescue cells from methotrexate toxicity.

L-5-MTHF (L-5-methyltetrahydrofolate) is the fully activated form — the one your cells actually use to power methylation and DNA synthesis. It’s what circulates in your blood after food folate has been metabolized. Supplemental versions (Quatrefolic®, Metafolin®) deliver it directly.

The clinical review that put the distinction on the map is blunt in its title: Folate, folic acid and 5-methyltetrahydrofolate are not the same thing [1].

What your body does with each

Folic acid enters circulation unchanged, gets taken up by the liver, and then must pass through a four-step enzymatic chain to reach 5-MTHF. The final and rate-limiting step is catalyzed by MTHFR. At normal food-fortification doses, healthy livers with normal MTHFR activity handle this reasonably well. At higher supplement doses, or in people with reduced MTHFR activity, the system can’t keep up — and unmetabolized folic acid (UMFA) accumulates in circulation [2][3].

Surveillance data has shown UMFA in essentially every US adult, child, and adolescent serum sample tested, with levels correlated to dietary folic acid intake [4][5]. The long-term implications are still debated; the short-term implication is clear — more folic acid doesn’t equal more usable folate, especially past a certain threshold.

Folinic acid enters the chain one step upstream of MTHFR. It still needs one enzymatic conversion to become 5-MTHF, but the step that’s most often impaired by MTHFR variants is bypassed. Folinic acid also feeds several folate-dependent pathways beyond methylation, including nucleotide synthesis — which is why it’s the form used in methotrexate rescue and in certain pediatric cerebral folate deficiency protocols.

L-5-MTHF skips the conversion chain entirely. It crosses into cells through specific folate transporters and is ready to donate its methyl group to the methylation cycle on arrival. No MTHFR activity required.

Q&A: If I have an MTHFR variant, is folic acid actively harmful?

Q: I tested positive for MTHFR C677T. I’ve read everything from “it doesn’t matter, just take folic acid” to “folic acid is toxic.” What’s true?

A: Neither extreme is quite right. Folic acid at food-fortification levels is not toxic. Most people, including most MTHFR heterozygotes, metabolize it adequately. The concern at high supplement doses — typically above 400–800 µg/day of folic acid in MTHFR-affected patients — is twofold: first, elevated UMFA in circulation without clear long-term benefit; second, an inefficient supply of usable folate to a system that needs the usable form. The clinician’s answer, supported by meta-analysis and mechanism, is: for MTHFR-affected patients, use bioactive folate (5-MTHF, with or without folinic acid). Skip the bottleneck; track homocysteine; adjust dose to biomarker. Methyl Folate Plus™ is the high-dose combination formula most of our practitioners reach for when clinical folate support is needed. For daily baseline with the full B-trio, Methylation Complete™ pairs 5-MTHF with methylcobalamin and B6 P5P.

Clinical profiles where each form fits

Folic acid is appropriate for:

• Adults without MTHFR variants, eating a varied diet, looking for simple baseline insurance
• Populations where food fortification is the intended intervention (public health, not individualized)
• Cost-sensitive contexts where folate inadequacy is a real risk and bioactive forms aren’t accessible

Folinic acid is appropriate for:

• Patients who want to feed multiple folate-dependent pathways beyond methylation (nucleotide synthesis, neurotransmitter precursors)
• Methylation-sensitive patients who feel overstimulated on high-dose 5-MTHF
• Specific clinical contexts: cerebral folate deficiency, methotrexate-related protocols (under physician guidance)

L-5-MTHF is appropriate for:

• Confirmed MTHFR C677T or A1298C carriers
• Patients with elevated homocysteine despite adequate dietary folate
• Pregnancy and preconception in MTHFR-affected women
• Patients with depression or mood issues where folate status is a suspected contributor — the evidence for L-methylfolate as an SSRI adjunct in depression is supported by two randomized trials at 15 mg/day [8], with broader reviews of folate and depression providing context [6][7]
• Patients with a history of recurrent miscarriage and known MTHFR variants

Many practitioner formulas combine 5-MTHF and folinic acid deliberately, because each feeds slightly different folate-dependent pathways. Methyl Folate Plus™ is built on exactly this logic.

Dosing, in broad strokes

Ranges reflect clinical practice, not prescriptions. Individualize with a practitioner.

• Baseline adult intake: 400 µg/day is the standard dietary reference intake. Most multis hit this.
• MTHFR heterozygous (one copy C677T or A1298C): 400–800 µg/day of L-5-MTHF is a common starting point.
• MTHFR homozygous or compound heterozygous: 800–1,600 µg/day (sometimes higher) of L-5-MTHF, often paired with folinic acid and B12.
• Depression adjunct protocols: 15 mg/day L-methylfolate in the randomized trials cited above — a clinical dose that should only be used under practitioner guidance.
• Preconception and pregnancy: bioactive folate at 600–1,200 µg/day for MTHFR-affected women is common practice; the exact dose depends on homocysteine, prior history, and provider guidance. Our folate in pregnancy article goes deeper.

How to read a supplement label

Four quick tells, in order from least to most clinically useful:

• “Folic acid” → synthetic, requires full conversion chain. Cheapest formulation.
• “Folate (from folic acid)” → same thing, relabeled. Read the parenthetical.
• “Folate (as L-5-MTHF)” / “Metafolin®” / “Quatrefolic®” → bioactive, ready to use. Metafolin is the calcium salt; Quatrefolic is the glucosamine salt; both are clinically interchangeable.
• “Folate (as folinic acid)” / “Calcium folinate” → partially active, bypasses MTHFR, feeds multiple pathways.

If the label simply says “folic acid” and you’re MTHFR-positive or symptomatic, that product is probably not for you.

The long-term picture

Two things to watch as the science keeps moving:

1. Unmetabolized folic acid is now detectable in essentially all US adults tested in recent surveillance work [4][5]. The clinical significance is still being sorted out, but the direction of the evidence favors bioactive forms for individualized supplementation, with food fortification remaining a separate public-health lever.

2. Folate, methylation, and mood remain tightly linked in the literature. Reviews of folate in depression — both alone and as an SSRI adjunct — consistently find that the bioactive forms produce measurable clinical effects where folic acid does not [9][10]. For patients with treatment-resistant symptoms and methylation-cycle variants, folate form is not a detail.

The short version

• Three forms of folate: folic acid (synthetic, needs conversion), folinic acid (partially activated, bypasses MTHFR), L-5-MTHF (fully activated, ready to use).
• MTHFR variants reduce the ability to activate folic acid by 30–70% — in those patients, bioactive forms matter.
• Unmetabolized folic acid is detectable in nearly all US adults; the long-term picture is still debated, but bioactive forms bypass the question.
• The best practitioner formulas pair 5-MTHF with folinic acid to feed multiple pathways.
• Dosing is individualized and should track homocysteine, not guesswork.

If you’re MTHFR-positive or symptomatic, Methyl Folate Plus™ delivers L-5-MTHF plus folinic acid plus B2/B3 cofactors — the folate side of a clinical methylation protocol. For a daily baseline with the full bioactive B trio (B12 methylcobalamin, B6 P5P, 5-MTHF), Methylation Complete™ is the sublingual we start most patients on.

---

This article is educational and does not constitute medical advice. Folate supplementation — especially at clinical doses — should be individualized and reviewed with a qualified practitioner, particularly during pregnancy or if you take prescription medications.

References

1. Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. 2014. PMID: 24494987
2. Sweeney MR, McPartlin J, Scott J. Folic acid fortification and public health: report on threshold doses above which unmetabolised folic acid appear in serum. BMC Public Health. 2007. PMID: 17378936
3. Raghubeer S, Matsha TE. Methylenetetrahydrofolate Reductase (MTHFR), the One-Carbon Cycle, and Cardiovascular Risks. Nutrients. 2021. PMID: 34960114
4. Pfeiffer CM, et al. Unmetabolized folic acid is detected in nearly all serum samples from US children, adolescents, and adults. J Nutr. 2015. PMID: 25733468
5. Plumptre L, et al. Association between Serum Unmetabolized Folic Acid Concentrations and Folic Acid from Fortified Foods. J Am Coll Nutr. 2017. PMID: 28895788
6. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev. 2008. PMID: 18950248
7. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009. PMID: 19909688
8. Papakostas GI, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012. PMID: 23212058
9. Sharpley AL, et al. Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry. 2012. PMID: 22762295
10. Kennedy DO. B Vitamins and the Brain: Mechanisms, Dose and Efficacy — A Review. Nutrients. 2016. PMID: 26828517